Clinical approval documents and related technologies for saisheng pharmaceutical to purchase new peptide drugs of category 1.1

Saisheng pharmaceutical announced on September 18, 2016 that recently, the company signed the technology transfer contract with Peking University Cancer Hospital and Beijing Institute of cancer prevention and control (hereinafter referred to as the "Institute of cancer prevention and control") and jiangyinsteyi Biotechnology Co., Ltd (hereinafter referred to as the "sityi"), In the contract signed between the company and the Institute of tumor prevention and control, it is agreed that the Institute of tumor prevention and control will transfer the clinical research approval documents, technology and related patents of its angiogenic peptide raw materials and preparations to the company; in the contract signed between the company and the Institute, it is agreed that the Institute will apply its angiogenic peptide to the fundus choroidal angiogenic diseases (including treatment age Research materials and technologies related to macular degeneration (AMD) are transferred to the company As a peptide drug, angiopoietin has mature synthesis process, stable and controllable quality, and its cost is lower than that of recombinant protein drugs and antibody drugs, which is conducive to reducing the medical expenditure of tumor patients, and has strong market competitiveness and broad market application prospects The project is consistent with the strategic R & D direction of the company's new drug reserve, which is conducive to improving the company's product structure, enriching the company's future product categories, and promoting the company's future long-term development About saisheng Pharmaceutical Co., Ltd Beijing saisheng Pharmaceutical Co., Ltd was wholly changed and established by Beijing saisheng Pharmaceutical Co., Ltd on July 28, 2011 It is now located at No 8, Xingsheng street, Beijing Economic and technological development, with a registered capital of 90 million yuan Founded in 1999, saisheng Pharmaceutical Co., Ltd is a high-tech enterprise specializing in research, development, production and sales of biological drugs (active protease, active polypeptide, active polysaccharide, amphoteric lipids) The research and development direction of the products are mainly natural or biotechnological drugs such as cardio cerebrovascular drugs, immune regulation drugs, nervous system drugs, etc After more than ten years of hard work and self-improvement, saisheng pharmaceutical industry has gradually established a high-tech industry integrating technology, innovation, sales and service, and a research and development platform for Biomacromolecule based on affinity chromatography separation and purification technology of antibody and antibody variable region At present, the company has a number of national pharmaceutical quasi brand products with precise clinical efficacy, exclusive or first production, and more than ten national invention patents At the same time, the company is the drafting unit of national standards for a number of drugs